Correction: Interleukin-6: a new therapeutic target

  • Josef S Smolen1 and

    Affiliated with

    • Ravinder N Maini2

      Affiliated with

      Arthritis Research & Therapy20068:407

      DOI: 10.1186/ar2065

      Published: 17 October 2006

      Following the publication of the above article [1], we noticed that due to an administrative oversight the Competing interests section was incomplete and should read as follows:

      JSS has received financial compensation from and served on advisory boards for Roche and is an investigator in clinical trials of tocilizumab. RNM has received consulting fees from Chugai; served on an ad hoc advisory board for Roche; and was responsible for the planning and preparation for publication of the Phase II European (CHARISMA) trial of tocilizumab with and without methotrexate. A patent for co-administration of methotrexate and tocilizumab for the treatment of rheumatoid arthritis, of which RNM is named as a co-inventor, has been applied for and fully assigned to Chugai.

      Authors’ Affiliations

      Professor of Medicine, Chairman Division of Rheumatology, Medical University of Vienna
      Emeritus Professor of Rheumatology, The Kennedy Institute of Rheumatology Division, Imperial College


      1. Smolen JS, Maini RN: Interleukin-6: a new therapeutic target. Arthritis Res Ther 2006,8(Suppl 2):S5.View ArticlePubMed


      © BioMed Central Ltd 2006